Executive summary: Japanese guidelines for allergic conjunctival diseases 2021
-
- Miyazaki Dai
- Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University
-
- Fukushima Atsuki
- Department of Ophthalmology, Saneikai Tsukazaki Hospital
-
- Uchio Eiichi
- Department of Ophthalmology, Fukuoka University, School of Medicine
-
- Shoji Jun
- Division of Ophthalmology, Department of Visual Sciences, Nihon University, School of Medicine
-
- Namba Kenichi
- Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Ebihara Nobuyuki
- Department of Ophthalmology, Juntendo University Urayasu Hospital
-
- Takamura Etsuko
- Department of Ophthalmology, Tokyo Women's Medical University, School of Medicine
-
- Fukuda Ken
- Department of Ophthalmology, Kochi Medical School
-
- Matsuda Akira
- Department of Ophthalmology, Juntendo University Urayasu Hospital
-
- Okamoto Shigeki
- Okamoto Eye Clinic
-
- Fukagawa Kazumi
- Ryogoku Eye Clinic
-
- Fujishima Hiroshi
- Department of Ophthalmology, Tsurumi University School of Dental Medicine
-
- Ohno Shigeaki
- Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Ohashi Yuichi
- Department of Ophthalmology, Ehime University School of Medicine
この論文をさがす
抄録
<p>Allergic conjunctival disease (ACD) is an inflammatory disease of the conjunctiva that is mainly caused by type I hypersensitivity response to allergens and accompanied by subjective symptoms and other findings induced by antigens. ACD is classified as allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. This article summarizes the third edition of the Japanese guidelines for allergic conjunctival diseases published in 2021 and outlines the diagnosis, pathogenesis, and treatment of ACD.<br>Since the introduction of immunosuppressive eye drops, the treatment strategies for severe ACDs have significantly changed. To clarify the recommended standard treatment protocols for ACD, the advantages and disadvantages of these treatments were assessed using clinical questions, with a focus on the use of steroids and immunosuppressive drugs. This knowledge will assist healthcare providers and patients in taking an active role in medical decision making.</p>
収録刊行物
-
- Allergology International
-
Allergology International 71 (4), 459-471, 2022
一般社団法人日本アレルギー学会
- Tweet
キーワード
詳細情報
-
- CRID
- 1390012235938577920
-
- ISSN
- 14401592
- 13238930
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可